Skip to main content
Premium Trial:

Request an Annual Quote

Serenex, Roche Ink Research Agreement

NEW YORK, Nov. 10 (GenomeWeb News) - Serenex said today that it has signed a deal to use its proteome mining and functional proteome fractionation technologies to screen small molecule drug compounds provided by Roche against multiple protein targets.

 

The companies will evaluate how effective Serenex's technologies are in helping Roche identify the most appropriate compounds to advance through the drug development pipeline, Serenex said.

 

Financial terms of the arrangement were not disclosed.